Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Multiple Myeloma Clinical Trials

Protocol Number Title
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
MT2003-13 Autologous Transplantation for Multiple Myeloma
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
MT2012-17R:Safety of Nplate? in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
MT2013-06C : Treatment of graft Failure after HSCT
MT2014-33R: Continued Long-Term Follow-up and Lenalidomide Maintenance Therapy for Patients Who have Enrolled on CTN 0702 (CTN 07LT)
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
Family-based studies of susceptibility to early onset disease
MT2015-11 : Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (CTN1302)
MT2016-04 Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination of Dendritic Cell/Myeloma Fusions (CTN 1401)
Expanded Access, Single Patient Use of Elotuzumab in Combination with Lenlidomide plus Dexamethasone for Multiple Myeloma
MT2015-32 : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
MT2015-21R: A follow-up study that evaluates the safety and clinical outcomes of subjects who have undergone hematopoietic stem cell transplantation with HSC835 (expanded umbilical cord blood hematopoietic stem cells)
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
MT2015-30 Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft vs. Host Disease
MT2016-13 :A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (CTN 1501)
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
MT2016-10: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease

20 trials displayed